150 participants enrolled into the PRESTIGE-AF trial

The PRESTIGE-AF trial has officially recruited 150 patients, which is a fantastic achievement and brings us closer to determining the best treatment for patients with atrial fibrillation who have suffered an intracerebral haemorrhage.

A special thank you goes to Dr Bernd Kallmünzer, Manuela Plischke, Anja Schmidt, Katherine Wallner, Petra Burkardt, Stefanie Balk, David Haupenthal and Bastian Volbers from Site 225, Universitätsklinikum Erlangen, who recruited the 150^th patient.

We have asked the Principal Investigator, Dr Bernd Kallmünzer, a few questions about the trial:

You have recruited 5 participants to the trial, how have you achieved this?

“Continuous screening, empathic and transparent communication with patients, regular team meetings.”

Why do you think it’s important to offer participation in the trial to all potential patients?

“Decisions on treatment should be based on scientific evidence. PRESTIGE-AF helps to generate evidence on a clinical relevant question.”

Why do you think PRESTIGE-AF is still a relevant and important trial to recruit to?

“Currently available evidence is not sufficient to use OAC after ICH in all patients. The evidence for alternative treatment options (e.g. LAAO) is still weak.”